ReviewThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2013
Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review.
Review in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.JAMA psychiatry · 2016Trial
- Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2015Trial
- Six-month postintervention depression and disability outcomes of in-home telehealth problem-solving therapy for depressed, low-income homebound older adults.Depression and anxiety · 2014Trial
- Molecular Basis of Late-Life Depression.International journal of molecular sciences · 2021Review
- Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association.Frontiers in psychiatry · 2020Article
- Advances in Pharmacotherapy of Late-Life Depression.Current psychiatry reports · 2018Review
- Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials.Neuropsychiatric disease and treatment · 2018Article
- Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study.EJNMMI research · 2017Article
- Depression in Homebound Older Adults: Recent Advances in Screening and Psychosocial Interventions.Current translational geriatrics and experimental gerontology reports · 2013Article
- Atypical antipsychotics as add-on treatment in late-life depression.Clinical interventions in agingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Many older adults with major depressive disorder (MDD) do not respond to antidepressant monotherapy. Although there are evidence-based treatment options to support treatment beyond monotherapy for adults, the evidence for such strategies, specifically in late-life MDD, is relatively scarce. This review examines the published data describing strategies for antidepressant augmentation or acceleration studied specifically in older adults, including lithium, stimulants, and second-generation antipsychotics. In addition, the authors suggest strategies for future research, such as study of specific agents, refining understanding of the impact of medical or cognitive comorbidity in late-life depression, and comparative effectiveness to examine methods already used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.